Market Closed -
Nasdaq
21:00:00 24/05/2024 BST
5-day change
1st Jan Change
3.44
USD
+4.24%
-5.23%
+132.43%
Trovagene, Inc. Announces Resignation of Dr. Stanley Tennant as Director, Effective December 31, 2018
December 14, 2018 at 09:31 pm
On December 10, 2018, Dr. Stanley Tennant resigned as a director of Trovagene, Inc. for personal reasons, effective December 31, 2018.
Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-02
CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study
04-08
CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating
03-06
MT
Sector Update: Health Care Stocks Rising Late Afternoon
03-01
MT
Sector Update: Health Care
03-01
MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy
03-01
MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating
03-01
MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024
02-29
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)
02-29
CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC
02-29
CI
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-29
CI
Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
11-02
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-02
CI
Top Premarket Gainers
27/09/23
MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields
27/09/23
DJ
Cardiff Oncology Reports 'Positive' Results From Onvansertib Monotherapy Trial for Pancreatic, Small Cell Lung Cancers
26/09/23
MT
Transcript : Cardiff Oncology, Inc. - Special Call
26/09/23
Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy
26/09/23
CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index
18/09/23
CI
North American Morning Briefing : Stock Futures -2-
16/08/23
DJ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating
11/08/23
MT
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
09/08/23
CI
Sector Update: Health Care Stocks Gaining Late Tuesday
08/08/23
MT
Sector Update: Health Care
08/08/23
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
More about the company
Last Close Price
3.44
USD
Average target price
9.833
USD
Spread / Average Target
+185.85%
Consensus
1st Jan change
Capi.
+132.43% 154M +67.53% 63.85B -0.77% 41.83B +45.66% 40.65B -10.72% 27.12B +13.30% 26.52B -22.79% 18.69B +4.70% 12.73B +24.10% 12.11B +27.41% 12.07B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1